Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etacizin vs propafenone in atrial fibrillation
2025-521267-13-01Phase 4Authorised
- Sponsor
- Olpha
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in Atrial fibrillation (AFib) comparing Etacizins with propafenone (2 arms). Primary endpoint: Recurrence of atrial fibrillation over 6 months of the treatment after restored sinus rhythm. Planned start Sep 2025; status: authorised.
02
Drugs
ethacizinepropafenone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2025-521267-13-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521267-13-01.